BACHURSKI, Patryk et al. Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025). Quality in Sport, [S. l.], v. 51, p. 68252, 2026. DOI: 10.12775/QS.2026.51.68252. Disponível em: https://apcz.umk.pl/QS/article/view/68252. Acesso em: 1 feb. 2026.